This site is intended for healthcare professionals

Sobi and Selecta Biosciences announce topline data of SEL 212 from the phase II COMPARE study supporting the potential for important clinical improvement in patients with chronic refractory gout.

Read time: 4 mins
Last updated:16th Mar 2021
Published:2nd Oct 2020
Condition: Gout
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest